Zealand Pharma A/S (ZEAL) Fair Value & Analysis
Healthcare · DK · Market cap 20.6B DKK
Strengths
Risks
Fair value as of: Aug 13, 2026
From 25 valuation models · updated 7 days ago
Fair value updated Aug 13, 2026, revised from kr 361.16 to kr 362.58 (+0.4%) since Jul 17, 2026. Share price +6.1% over the past month.
A solid business, screening 15% undervalued on our models.
What matters now
- The model range is unusually wide (kr 227.56 to kr 1,116). The outcome hinges heavily on assumptions, so read the point estimate with caution.
- Our model range runs from kr 227.56 (bear) to kr 1,116 (bull), base kr 362.58. The closer the price sits to the lower half, the larger the margin of safety.
- Quality 71/100 (solid quality) with high evidence: the data supports the verdict.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range kr 71.95 – kr 954.00 · fair‑value band kr 227.56 – kr 1,116 · the kr 314.60 price screens below the kr 362.58 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Zealand Pharma A/S (ZEAL) currently trades at kr 314.60, while our model-based Fair Value estimate is kr 362.58, implying the stock looks roughly 15.3% undervalued today. The Quality Score stands at 71/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Zealand Pharma A/S generated revenue of 9.2B DKK at a net margin of 69.2%. It earns a return on equity of 56.2%. The balance sheet holds a net cash position of 4.1B DKK. The stock trades on a trailing P/E of 3.5. Fundamentals as of Aug 13, 2026
Our scenario range runs from kr 227.56 (bear case) to kr 1,116 (bull case); at kr 314.60, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. Analysts expect earnings well below the last reported figure (earnings in transition, for example expiring patents or contracts); a fair value that looks fair on trailing earnings may then be too optimistic. The share trades about 43% below its 52-week high and 35% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -63% fair-value upside, at 15%, ZEAL screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 25 models by family
Widest divergence: Growth Earnings (kr 4,351) versus Asset-Based (kr 144.18). Highest evidence: Growth DCF (80).
Notify me when ZEAL reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 73 · Market factors (momentum, volatility) 30
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs.
Full company description
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Zealand Pharma A/S reported revenue of kr 9.2B in FY2025 versus kr 293M in FY2021, a compound +136.9%/yr. Reported net income was kr 6.5B in FY2025.
Watch ZEAL: get an alert when its fair value changes →
Earlier news
External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.
- Zealand Pharma conference call on August 13 at 2pm CEST (8am ET) to present second quarter 2026 financial results
- Zealand Pharma - Transactions related to share buy-back program (week 31, 2026)
- Zealand Pharma - Transactions related to share buy-back program (week 30, 2026)
- Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely asso
Peer Group
Biotechnology · 623 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Biotechnology median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Insider activity: 40/100
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $525.73 | $278.78 | -47% |
| Samsung Biologics Co 207940 | 1,549,000 KRW | 1,055,793 KRW | -32% |
| Celltrion, Inc 068270 | 202,000 KRW | 74,519 KRW | -63% |
| WuXi Biologics (Cayman) Inc 2269 | HK$45.70 | HK$30.58 | -33% |
| Innovent Biologics, Inc 1801 | HK$95.55 | HK$19.68 | -79% |
| Genmab A/S GMAB | kr 2,104 | kr 250.07 | -88% |
| Sino Biopharmaceutical Limited 1177 | HK$4.87 | HK$3.37 | -31% |
| RemeGen Co 688331 | ¥131.87 | ¥23.19 | -82% |
| ALTEOGEN Inc 196170 | 314,000 KRW | 39,476 KRW | -87% |
| Biocon Limited BIOCON | ₹417.50 | ₹52.10 | -88% |
Compare Zealand Pharma A/S with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Discover undervalued stocks
Pick a strategy and jump into the live analysis with that exact screen applied.
Discover tools
Frequently asked questions
Is Zealand Pharma A/S (ZEAL) overvalued or undervalued?
What is the fair value of ZEAL?
What is the quality score of ZEAL?
What is the revenue of Zealand Pharma A/S (ZEAL)?
What is the net profit margin of ZEAL?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Zealand Pharma A/S and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.